ticlopidine has been researched along with Intermittent Claudication in 50 studies
Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.
Intermittent Claudication: A symptom complex characterized by pain and weakness in SKELETAL MUSCLE group associated with exercise, such as leg pain and weakness brought on by walking. Such muscle limpness disappears after a brief rest and is often relates to arterial STENOSIS; muscle ISCHEMIA; and accumulation of LACTATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim was to test within a randomized double-blind trial whether the platelet inhibitor ticlopidine might improve peripheral blood flow and distal pressures in patients with aortofemoral arteriosclerosis." | 9.07 | Long-term effects of ticlopidine on lower limb blood flow, ankle/brachial index and symptoms in peripheral arteriosclerosis. A double-blind study. The STIMS Group in Lund. Swedish Ticlopidine Multicenter Study. ( Fagher, B, 1994) |
| "The Swedish Ticlopidine Multicentre Study (STIMS) was a double-blind placebo-controlled trial designed to determine whether ticlopidine, a platelet antiaggregatory agent, reduces the incidence of myocardial infarction, stroke and transitory ischaemic attacks in patients with intermittent claudication." | 9.06 | Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. ( Almgren, B; Bergqvist, D; Boberg, J; Boberg, M; Eriksson, I; Fagher, B; Janzon, L; Kjellström, T; Lindgärde, F; Persson, G, 1990) |
| "After a 3-month, single-blind, run-in period, 151 patients with intermittent claudication were randomly allocated to receive the antiplatelet agent ticlopidine (250 mg twice per day) or an identical placebo." | 9.06 | Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. ( Balsano, F; Catalano, M; Coccheri, S; Fortunato, G; Grasselli, S; Hellemans, H; Libretti, A; Nenci, GG; Vanhove, P; Violi, F, 1989) |
| "In this multicenter trial 169 patients with chronic intermittent claudication due to obstructive peripheral vascular disease were randomized in a double-blind fashion into two parallel groups receiving either 250 mg ticlopidine or placebo, twice daily." | 9.06 | Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. ( Arcan, JC; Blanchard, J; Boissel, JP; Destors, JM; Panak, E, 1988) |
| "Fifty-one men with atherosclerotic intermittent claudication and haemorheological abnormalities completed a double-blind, one-year randomised trial of Ticlopidine (500 mg/day), a new antiplatelet agent." | 9.05 | Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. ( Aukland, A; George, AJ; Hurlow, RA; Stuart, J, 1982) |
| "Data from 67 patients with intermittent claudication taking part in a randomised controlled trial and who received clopidogrel in addition to aspirin was analysed." | 7.73 | Variability in responsiveness to clopidogrel in patients with intermittent claudication. ( Bachoo, P; Brittenden, J; Cassar, K; Ford, I; Greaves, M, 2006) |
| "The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (IC) model in comparison with nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), ticlopidine (5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrochloride) and cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone)." | 7.72 | Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| " Finally, the chronic administration of C plus T for twelve months induced a further improvement of all considered parameters." | 6.68 | Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. ( Abrignani, MG; Caruso, R; Geraci, AM; Longo, B; Novo, S; Pavone, G; Pernice, C; Strano, A; Zamueli, M, 1996) |
| " The aim of this study was to determine whether combination of aspirin and clopidogrel affects thrombin-antithrombin III and D-dimer in patients with intermittent claudication undergoing angioplasty, compared with aspirin alone." | 5.11 | Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty. ( Bachoo, P; Brittenden, J; Cassar, K; Ford, I; Greaves, M, 2005) |
| "To study the effect of long-term treatment of the platelet inhibitor ticlopidine as secondary prevention against the need of vascular surgery in patients with intermittent claudication." | 5.08 | Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS). ( Almgren, B; Bergqvist, D; Dickinson, JP, 1995) |
| "The mortality in patients with intermittent claudication can be reduced by treatment with ticlopidine." | 5.08 | The STIMS trial: the ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study. ( Janzon, L, 1996) |
| "The aim was to test within a randomized double-blind trial whether the platelet inhibitor ticlopidine might improve peripheral blood flow and distal pressures in patients with aortofemoral arteriosclerosis." | 5.07 | Long-term effects of ticlopidine on lower limb blood flow, ankle/brachial index and symptoms in peripheral arteriosclerosis. A double-blind study. The STIMS Group in Lund. Swedish Ticlopidine Multicenter Study. ( Fagher, B, 1994) |
| "EMATAP, a randomized stratified, placebo-controlled double-blind multicentre trial was performed in Argentina in order to confirm the effect of ticlopidine in the prevention of thrombotic events in patients with intermittent claudication." | 5.07 | Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. ( Blanchard, J; Carreras, LO; Kindermans, M, 1994) |
| "The Swedish Ticlopidine Multicentre Study (STIMS) was a double-blind placebo-controlled trial designed to determine whether ticlopidine, a platelet antiaggregatory agent, reduces the incidence of myocardial infarction, stroke and transitory ischaemic attacks in patients with intermittent claudication." | 5.06 | Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. ( Almgren, B; Bergqvist, D; Boberg, J; Boberg, M; Eriksson, I; Fagher, B; Janzon, L; Kjellström, T; Lindgärde, F; Persson, G, 1990) |
| "This study meta-analysed randomized, double-blind, placebo controlled trials in patients with intermittent claudication of the lower limbs comparing ticlopidine to placebo in order to test the hypothesis that the drug, a pure antiplatelet agent, is able to reduce the incidence of thrombotic cardio-vascular events on atherosclerotic arteries in these patients." | 5.06 | Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs? ( Boissel, JP; Destors, JM; Peyrieux, JC, 1989) |
| "In this multicenter trial 169 patients with chronic intermittent claudication due to obstructive peripheral vascular disease were randomized in a double-blind fashion into two parallel groups receiving either 250 mg ticlopidine or placebo, twice daily." | 5.06 | Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. ( Arcan, JC; Blanchard, J; Boissel, JP; Destors, JM; Panak, E, 1988) |
| " for 21 months) on fibrinogen and other rheological variables, as compared to placebo, were studied in 44 patients with intermittent claudication due to peripheral arterial occlusive disease." | 5.06 | Long-term effects of ticlopidine on fibrinogen and haemorheology in patients with peripheral arterial disease. ( Balestra, V; Coccheri, S; Palareti, G; Poggi, M; Torricelli, P, 1988) |
| "Fifty-one men with atherosclerotic intermittent claudication and haemorheological abnormalities completed a double-blind, one-year randomised trial of Ticlopidine (500 mg/day), a new antiplatelet agent." | 5.05 | Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. ( Aukland, A; George, AJ; Hurlow, RA; Stuart, J, 1982) |
| "This review focuses on the use of clopidogrel and the phenomenon of HCPR in PAD patients treated for intermittent claudication or critical limb ischaemia (CLI)." | 4.90 | Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures. ( Diamantopoulos, A; Katsanos, K; Pastromas, G; Spiliopoulos, S, 2014) |
| " Among the key recommendations in this chapter are the following: For patients with chronic limb ischemia, we recommend lifelong aspirin therapy in comparison to no antiplatelet therapy in patients with clinically manifest coronary or cerebrovascular disease (Grade 1A) and in those without clinically manifest coronary or cerebrovascular disease (Grade 1C+)." | 4.82 | Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. ( Clagett, GP; Jackson, MR; Lip, GY; Sobel, M; Tangelder, M; Verhaeghe, R, 2004) |
| "This study was conducted to determine whether there is additive benefit of dual-antiplatelet therapy (DAPT) with aspirin (acetylsalicylic acid [ASA]) and clopidogrel compared with ASA monotherapy among patients with symptomatic peripheral arterial disease." | 3.81 | Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. ( Amsterdam, EA; Anderson, DR; Armstrong, EJ; Bang, H; Freischlag, JA; Laird, JR; Singh, GD; Yeo, KK, 2015) |
| "Intermittent claudication has changed from being only a disabling symptom to being an indication for secondary prevention of coronary and cerebrovascular events." | 3.77 | [Role of antiaggregants in the treatment of arterial diseases of the lower limbs]. ( Boissel, JP, 1991) |
| "Data from 67 patients with intermittent claudication taking part in a randomised controlled trial and who received clopidogrel in addition to aspirin was analysed." | 3.73 | Variability in responsiveness to clopidogrel in patients with intermittent claudication. ( Bachoo, P; Brittenden, J; Cassar, K; Ford, I; Greaves, M, 2006) |
| "The systemic treatment effects of OP-1206 alpha-CD (17S-20-dimethyl-trans-delta 2-PGE1 alpha-cyclodextrin clathrate), a prostaglandin E1 (PGE1) analogue, on walking dysfunction, spinal cord blood flow (SCBF) and skin blood flow (SKBF) were assessed in the rat neuropathic intermittent claudication (IC) model in comparison with nifedipine (dimethyl 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylate), ticlopidine (5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno[3,2-C]pyridine hydrochloride) and cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)-butoxy]-3,4-dihydro-2(1H)-quinolinone)." | 3.72 | Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol. ( Akimaru, S; Ito, H; Katsube, N; Maegawa, H; Marsala, M; Nakai, K; Takenobu, Y; Takimizu, H, 2003) |
| "To assess the effect of ticlopidine on the cutaneous circulation, 25 patients with lower limb ischemia were investigated just before and at two hours after being given a 200 mg oral dose of ticlopidine." | 3.68 | Effect of ticlopidine on the cutaneous circulation in peripheral vascular disease. ( Iwai, T; Qian, S, 1993) |
| "Peripheral artery disease is considered to be a manifestation of systemic atherosclerosis with associated adverse cardiovascular and limb events." | 2.84 | Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. ( Baumgartner, I; Berger, JS; Blomster, J; Fowkes, FG; Heizer, G; Held, P; Hiatt, WR; Jones, WS; Katona, BG; Mahaffey, KW; Millegård, M; Norgren, L; Patel, MR; Reist, C, 2017) |
| " Finally, the chronic administration of C plus T for twelve months induced a further improvement of all considered parameters." | 2.68 | Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. ( Abrignani, MG; Caruso, R; Geraci, AM; Longo, B; Novo, S; Pavone, G; Pernice, C; Strano, A; Zamueli, M, 1996) |
| "In the peripheral arteries, a thrombus superimposed on atherosclerosis contributes to the progression of peripheral artery disease (PAD), producing intermittent claudication (IC), ischemic necrosis, and, potentially, loss of the limb." | 2.50 | Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease. ( Cafaro, G; de Gaetano, G; Di Minno, A; Di Minno, G; Lupoli, R; Petitto, M; Spadarella, G; Tremoli, E, 2014) |
| "Intermittent claudication is a common disabling condition that affects approximately 5% to 15% of patients with atherosclerotic disease." | 2.41 | Can claudication be improved with medication? ( Conners, MS; Money, SR, 2002) |
| "Atorvastatin 80 mg was found to be independent predictor of survival, and major amputation was found to be independent predictor of mortality." | 1.39 | Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry). ( Buszman, PE; Buszman, PP; Kiesz, RS; Konkolewska, MD; Martin, JL; Radvany, MG; Szymanski, R; Wiernek, BK; Wiernek, SL, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (18.00) | 18.7374 |
| 1990's | 12 (24.00) | 18.2507 |
| 2000's | 22 (44.00) | 29.6817 |
| 2010's | 7 (14.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Di Minno, G | 1 |
| Spadarella, G | 1 |
| Cafaro, G | 1 |
| Petitto, M | 1 |
| Lupoli, R | 1 |
| Di Minno, A | 1 |
| de Gaetano, G | 1 |
| Tremoli, E | 1 |
| Spiliopoulos, S | 1 |
| Pastromas, G | 1 |
| Diamantopoulos, A | 1 |
| Katsanos, K | 1 |
| Armstrong, EJ | 1 |
| Anderson, DR | 1 |
| Yeo, KK | 1 |
| Singh, GD | 1 |
| Bang, H | 1 |
| Amsterdam, EA | 1 |
| Freischlag, JA | 1 |
| Laird, JR | 1 |
| Dake, MD | 1 |
| Ansel, GM | 1 |
| Jaff, MR | 1 |
| Ohki, T | 1 |
| Saxon, RR | 1 |
| Smouse, HB | 1 |
| Machan, LS | 1 |
| Snyder, SA | 1 |
| O'Leary, EE | 1 |
| Ragheb, AO | 1 |
| Zeller, T | 1 |
| Hiatt, WR | 2 |
| Fowkes, FG | 1 |
| Heizer, G | 1 |
| Berger, JS | 1 |
| Baumgartner, I | 1 |
| Held, P | 1 |
| Katona, BG | 1 |
| Mahaffey, KW | 1 |
| Norgren, L | 1 |
| Jones, WS | 1 |
| Blomster, J | 1 |
| Millegård, M | 1 |
| Reist, C | 1 |
| Patel, MR | 1 |
| Meltzer, AJ | 1 |
| Da Silva, P | 1 |
| Schneider, DB | 1 |
| Shrikhande, GV | 1 |
| Kiesz, RS | 1 |
| Wiernek, SL | 1 |
| Wiernek, BK | 1 |
| Radvany, MG | 1 |
| Buszman, PP | 1 |
| Szymanski, R | 1 |
| Konkolewska, MD | 1 |
| Martin, JL | 1 |
| Buszman, PE | 1 |
| Degischer, S | 2 |
| Labs, KH | 3 |
| Hochstrasser, J | 1 |
| Aschwanden, M | 2 |
| Tschoepl, M | 1 |
| Jaeger, KA | 3 |
| Olin, JW | 1 |
| Conners, MS | 1 |
| Money, SR | 1 |
| Dörffler-Melly, J | 1 |
| Schmidli, J | 1 |
| Mahler, F | 1 |
| Fiotti, N | 1 |
| Altamura, N | 1 |
| Cappelli, C | 1 |
| Schillan, M | 1 |
| Guarnieri, G | 1 |
| Giansante, C | 1 |
| Nakai, K | 1 |
| Takenobu, Y | 1 |
| Takimizu, H | 1 |
| Akimaru, S | 1 |
| Maegawa, H | 1 |
| Ito, H | 1 |
| Marsala, M | 1 |
| Katsube, N | 1 |
| Wilhite, DB | 1 |
| Comerota, AJ | 2 |
| Schmieder, FA | 1 |
| Throm, RC | 1 |
| Gaughan, JP | 1 |
| Rao, AK | 1 |
| Clagett, GP | 1 |
| Sobel, M | 1 |
| Jackson, MR | 1 |
| Lip, GY | 1 |
| Tangelder, M | 1 |
| Verhaeghe, R | 1 |
| Cavendish, JJ | 1 |
| Safani, M | 1 |
| Cassar, K | 3 |
| Ford, I | 3 |
| Greaves, M | 3 |
| Bachoo, P | 3 |
| Brittenden, J | 3 |
| Tulsyan, N | 1 |
| Ouriel, K | 1 |
| Kashyap, VS | 1 |
| Krantz, MJ | 1 |
| Singer, E | 1 |
| Imfeld, S | 2 |
| Hoffmann, U | 1 |
| Buschmann, I | 1 |
| Singer, L | 1 |
| Thalhammer, C | 1 |
| Zatevakhin, II | 1 |
| Zolkin, VN | 1 |
| Shiller, EE | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Andreozzi, GM | 1 |
| Arosio, E | 1 |
| Martini, R | 1 |
| Verlato, F | 1 |
| Visonà, A | 1 |
| Verstraete, M | 2 |
| Hawker, RJ | 1 |
| Aukland, A | 2 |
| Hurlow, RA | 1 |
| George, AJ | 1 |
| Stuart, J | 1 |
| Bergqvist, D | 2 |
| Almgren, B | 2 |
| Dickinson, JP | 1 |
| Kirichenko, AA | 1 |
| Prekina, VI | 1 |
| Repinskaia, NP | 1 |
| Novichkova, IuN | 1 |
| Ter-Gevondian, NM | 1 |
| Vinogradova, IV | 1 |
| Fagher, B | 3 |
| Blanchard, J | 2 |
| Carreras, LO | 1 |
| Kindermans, M | 1 |
| Qian, S | 1 |
| Iwai, T | 1 |
| Persson, S | 1 |
| Persson, G | 2 |
| Larsson, H | 1 |
| Novo, S | 1 |
| Abrignani, MG | 1 |
| Pavone, G | 1 |
| Zamueli, M | 1 |
| Pernice, C | 1 |
| Geraci, AM | 1 |
| Longo, B | 1 |
| Caruso, R | 1 |
| Strano, A | 1 |
| Janzon, L | 2 |
| Pérez Encinas, M | 1 |
| Fernández, MA | 1 |
| Martín, ML | 1 |
| Calvo, MV | 1 |
| Gómez-Alonso, A | 1 |
| Dominguez-Gil, A | 1 |
| Lozano, F | 1 |
| Frangos, SG | 1 |
| Chen, AH | 1 |
| Sumpio, B | 1 |
| Boissel, JP | 3 |
| Boberg, J | 1 |
| Boberg, M | 1 |
| Eriksson, I | 1 |
| Lindgärde, F | 1 |
| Kjellström, T | 1 |
| McTavish, D | 1 |
| Faulds, D | 1 |
| Goa, KL | 1 |
| Balsano, F | 1 |
| Coccheri, S | 2 |
| Libretti, A | 1 |
| Nenci, GG | 1 |
| Catalano, M | 1 |
| Fortunato, G | 1 |
| Grasselli, S | 1 |
| Violi, F | 1 |
| Hellemans, H | 1 |
| Vanhove, P | 1 |
| Arcan, JC | 2 |
| Panak, E | 2 |
| Peyrieux, JC | 1 |
| Destors, JM | 2 |
| Palareti, G | 1 |
| Poggi, M | 1 |
| Torricelli, P | 1 |
| Balestra, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Controlled, Superiority Clinical Trial to Evaluate the Safety and Efficacy of Drug-eluting Peripheral Arterial Stent System（G-stream） in the Treatment of the Above-the-knee Femoropopliteal Artery Stenosis or Occlusion[NCT05780359] | 280 participants (Anticipated) | Interventional | 2022-05-27 | Recruiting | |||
| Evaluation of the Zilver PTX Drug-Eluting Stent in the Above-the-Knee Femoropopliteal Artery[NCT00120406] | 474 participants (Actual) | Interventional | 2005-03-31 | Completed | |||
| A Randomized, Double-blind, Parallel Group, Multicentre Phase IIIb Study to Compare Ticagrelor With Clopidogrel Treatment on the Risk of Cardiovascular Death, Myocardial Infarction and Ischemic Stroke in Patients With Established Peripheral Artery Disease[NCT01732822] | Phase 3 | 13,885 participants (Actual) | Interventional | 2012-12-04 | Completed | ||
| "Exercise Therapy in Patients With Peripheral Arterial Disease: the Costs and Effectiveness of Physiotherapeutic Supervision With or Without Therapy Feedback Versus a go Home and Walk Advice"[NCT00279994] | 300 participants (Anticipated) | Interventional | 2005-12-31 | Active, not recruiting | |||
| A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Critic Ischemia of Lower Limbs While Administering Positive CD133 Mobilized With G-CSF[NCT00765050] | Phase 1/Phase 2 | 13 participants (Actual) | Interventional | 2009-01-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Event-free survival is defined as freedom from the major adverse events of death, target lesion revascularization, target limb ischemia requiring surgical intervention (bypass or amputation of toe, foot or leg), surgical repair of the target vessel (e.g., dissection requiring surgery), and from worsening of the Rutherford classification by 2 classes or to class 5 or 6.~Participant flow is based on initial randomization of Zilver PTX or PTA (Percutaneous balloon angioplasty), and Event-free survival is based on Per-Protocol analysis where only patients who were treated according to their initial randomization are counted." (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 90.4 |
| PTA (Control) | 83.9 |
Primary patency is defined as a Peak systolic velocity (PSV) ratio < 2.0 or angiographic percent diameter stenosis < 50%. (NCT00120406)
Timeframe: 12 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Zilver PTX | 82.7 |
| PTA (Control) | 32.7 |
Participants with ALI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 117 |
| Clopidogrel 75 mg od | 115 |
Participants with all-cause death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 628 |
| Clopidogrel 75 mg od | 635 |
Participants with any amputation caused by peripheral arterial disease (PAD). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 179 |
| Clopidogrel 75 mg od | 208 |
Participants with any revascularization. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1211 |
| Clopidogrel 75 mg od | 1250 |
Participants with CV death, myocardial infarction (MI) or ischemic stroke. If no event, censoring occurs at the minimum of (primary analysis censoring date (PACD), last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participants (Number) |
|---|---|
| Ticagrelor 90 mg bd | 751 |
| Clopidogrel 75 mg od | 740 |
Participants with CV death, MI or all-cause stroke. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 766 |
| Clopidogrel 75 mg od | 759 |
Participants with CV death, MI, ischemic stroke or acute limb ischemia (ALI). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 839 |
| Clopidogrel 75 mg od | 833 |
Participants with CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 363 |
| Clopidogrel 75 mg od | 343 |
Participants with hospitalization associated with CV death, hospitalization due to MI, ischemic stroke, lower extremity revascularization, major amputation due to PAD, transient ischemic attack (TIA), coronary revascularization or unstable angina. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1312 |
| Clopidogrel 75 mg od | 1314 |
Participants with lower extremity revascularization (LER). If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 846 |
| Clopidogrel 75 mg od | 892 |
Participants with major amputation caused by PAD. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 100 |
| Clopidogrel 75 mg od | 116 |
Participants with MI. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 349 |
| Clopidogrel 75 mg od | 334 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1119 |
| Clopidogrel 75 mg od | 1140 |
Participants with all-cause death, MI, ischemic stroke, ALI, major amputation or Thrombolysis in Myocardial Infarction (TIMI) major bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 1183 |
| Clopidogrel 75 mg od | 1199 |
Participants with all-cause death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 983 |
| Clopidogrel 75 mg od | 992 |
Participants with CV death, MI, ischemic stroke, fatal bleeding or intracranial bleeding. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, non-CV death date) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 789 |
| Clopidogrel 75 mg od | 786 |
Participants with non-CV death. If no event, censoring occurs at the minimum of (PACD, last endpoint assessment date, CV death) (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 250 |
| Clopidogrel 75 mg od | 272 |
Participants with PLATO major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 206 |
| Clopidogrel 75 mg od | 188 |
Participants with a permanent discontinuation of study drug due to any bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 168 |
| Clopidogrel 75 mg od | 112 |
Participants with TIMI major bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 113 |
| Clopidogrel 75 mg od | 109 |
Participants with TIMI major or minor bleeding event. If no event, censoring occurs at the minimum of (last endpoint assessment date, death date, 7 days after last dose of study drug) (NCT01732822)
Timeframe: From the date of first dose and up to and including 7 days following the date of last dose of study drug
| Intervention | Participant (Number) |
|---|---|
| Ticagrelor 90 mg bd | 193 |
| Clopidogrel 75 mg od | 175 |
"Change in ankle brachial index (ABI) / toe brachial index (TBI).~Ankle brachial index (ABI) is the ratio of blood pressures from the ankle and arm and is used for diagnosing peripheral arterial occlusive disease (PAOD):~Normal: 1 to 1.29 Borderline: 0.91 to 0.99 Mild PAOD: 0.71 to 0.90 Medium severe PAOD: 0.41 to 0.7 Severe PAOD: <0.4~Toe brachial index (TBI) is the ratio between the toe pressure and the higher brachial pressure, used for diagnosing PAOD when the ABI cannot be used:~Normal: >0.7 Mild: 0.5-0.7 Moderate: 0.35-0.5 Moderate-Severe: <0.35 and toe pressure 40 mmHg Severe: <0.35 and toe pressure < 30 mmHg" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Change in ABI/TBI (Mean) | |||
|---|---|---|---|---|
| ABI - 6 months N = 6184(Tica), 6319(Clopi) | ABI - End of treatment N = 4951(Tica), 5073(Clopi) | TBI - 6 months N = 55(Tica), 48(Clopi) | TBI - End of treatment N = 36(Tica), 21(Clopi) | |
| Clopidogrel 75 mg od | 0.011 | 0.016 | 0.036 | -0.065 |
| Ticagrelor 90 mg bd | 0.016 | 0.022 | 0.050 | 0.059 |
"Progression of the clinical/symptomatic status of the limb by changes in Fontaine stage.~Stage I - Asymptomatic Stage IIa - Intermittent claudication after more than 200 meters of pain free walking Stage IIb - Intermittent claudication after less than 200 meters of walking Stage III - Rest pain Stage IV - Ischemic ulcers or gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) | |||||
|---|---|---|---|---|---|---|
| Stage I - End of treatment | Stage IIa - End of treatment | Stage IIb - End of treatment | Stage III - End of treatment | Stage IV - End of treatment | Missing - End of treatment | |
| Clopidogrel - Stage I | 743 | 230 | 56 | 9 | 4 | 250 |
| Clopidogrel - Stage IIa | 723 | 1956 | 311 | 15 | 7 | 724 |
| Clopidogrel - Stage IIb | 198 | 557 | 450 | 23 | 10 | 370 |
| Clopidogrel - Stage III | 33 | 33 | 38 | 23 | 5 | 60 |
| Clopidogrel - Stage IV | 19 | 21 | 15 | 12 | 13 | 45 |
| Ticagrelor - Stage I | 775 | 227 | 45 | 7 | 7 | 248 |
| Ticagrelor - Stage IIa | 683 | 1948 | 269 | 24 | 7 | 743 |
| Ticagrelor - Stage IIb | 171 | 560 | 469 | 12 | 5 | 403 |
| Ticagrelor - Stage III | 15 | 41 | 39 | 31 | 1 | 59 |
| Ticagrelor - Stage IV | 26 | 28 | 19 | 7 | 13 | 47 |
"Progression of the clinical/symptomatic status of the limb by changes in Rutherford classification.~Category 0 - Asymptomatic Category 1 - Mild claudication Category 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters.~Category 3 - Severe claudication Category 4 - Rest pain Category 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Category 6 - Severe ischemic ulcers or frank gangrene" (NCT01732822)
Timeframe: From randomization to PACD, an average of 2.5 years
| Intervention | Participant (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Category 0 - End of treatment | Category 1/2 - End of treatment | Category 3 - End of treatment | Category 4 - End of treatment | Category 5 - End of treatment | Category 6 - End of treatment | Missing - End of treatment | |
| Clopidogrel - Cat 0 | 743 | 230 | 56 | 9 | 2 | 2 | 250 |
| Clopidogrel - Cat 1/2 | 723 | 1956 | 311 | 15 | 6 | 1 | 724 |
| Clopidogrel - Cat 3 | 198 | 557 | 450 | 23 | 6 | 4 | 370 |
| Clopidogrel - Cat 4 | 33 | 33 | 38 | 23 | 4 | 1 | 60 |
| Clopidogrel - Cat 5 | 13 | 18 | 12 | 11 | 12 | 0 | 34 |
| Clopidogrel - Cat 6 | 6 | 3 | 3 | 1 | 1 | 0 | 11 |
| Ticagrelor - Cat 0 | 775 | 227 | 45 | 7 | 5 | 2 | 248 |
| Ticagrelor - Cat 3 | 171 | 560 | 469 | 12 | 3 | 2 | 403 |
| Ticagrelor - Cat 4 | 15 | 41 | 39 | 31 | 1 | 0 | 59 |
| Ticagrelor - Cat 5 | 23 | 23 | 13 | 4 | 11 | 0 | 33 |
| Ticagrelor - Cat 6 | 3 | 5 | 6 | 3 | 0 | 2 | 14 |
| Ticagrelor - Stage II | 683 | 1948 | 269 | 24 | 4 | 3 | 743 |
13 reviews available for ticlopidine and Intermittent Claudication
| Article | Year |
|---|---|
Systematic reviews and meta-analyses for more profitable strategies in peripheral artery disease.
Topics: Adenosine; Aspirin; Asymptomatic Diseases; Cilostazol; Clopidogrel; Fibrinolytic Agents; Humans; Int | 2014 |
Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures.
Topics: Blood Platelets; Clopidogrel; Endovascular Procedures; Humans; Intermittent Claudication; Peripheral | 2014 |
Management of patients with intermittent claudication.
Topics: Aspirin; Blood Vessel Prosthesis; Cilostazol; Clopidogrel; Exercise Therapy; Humans; Intermittent Cl | 2002 |
Can claudication be improved with medication?
Topics: Carnitine; Cilostazol; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Platelet Aggrega | 2002 |
Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Topics: Arterial Occlusive Diseases; Aspirin; Cilostazol; Clopidogrel; Contraindications; Evidence-Based Med | 2004 |
Effect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination.
Topics: Aspirin; Bleeding Time; Blood Platelets; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; | 2005 |
Emerging drugs in peripheral arterial disease.
Topics: Administration, Oral; Anticoagulants; Arterial Occlusive Diseases; Arteries; Aspirin; Clopidogrel; D | 2006 |
Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication.
Topics: Aspirin; Atherosclerosis; Clopidogrel; Drug Therapy, Combination; Humans; Intermittent Claudication; | 2006 |
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; H | 1984 |
Vascular drugs in the new millennium.
Topics: Abciximab; Animals; Anistreplase; Antibodies, Monoclonal; Anticoagulants; Aspirin; Chondroitin Sulfa | 2000 |
What can I do to continue walking despite intermittent claudication?
Topics: Aspirin; Cilostazol; Clopidogrel; Humans; Intermittent Claudication; Tetrazoles; Ticlopidine; Vasodi | 2001 |
[Role of antiaggregants in the treatment of arterial diseases of the lower limbs].
Topics: Humans; Intermittent Claudication; Ketanserin; Leg; Meta-Analysis as Topic; Peripheral Vascular Dise | 1991 |
Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders.
Topics: Adult; Aged; Blood Platelets; Cerebrovascular Disorders; Coronary Disease; Drug Interactions; Humans | 1990 |
25 trials available for ticlopidine and Intermittent Claudication
| Article | Year |
|---|---|
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combine | 2016 |
Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease.
Topics: Adenosine; Aged; Cardiovascular Diseases; Clopidogrel; Double-Blind Method; Female; Hemorrhage; Huma | 2017 |
Long term prognosis in patients with peripheral arterial disease treated with antiplatelet agents.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Cause of Death; Female; Follow-Up | 2003 |
Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Bleeding Time; Cilostazol; Clopidogrel; Drug Therapy, Co | 2003 |
Randomized clinical trial of the antiplatelet effects of aspirin-clopidogrel combination versus aspirin alone after lower limb angioplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, | 2005 |
Clopidogrel has no effect on D-dimer and thrombin-antithrombin III levels in patients with peripheral arterial disease undergoing peripheral percutaneous transluminal angioplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Ster | 2005 |
Aspirin in peripheral arterial disease: breakthrough or pitfall?
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Collateral Circulation; Combined Modality Therapy | 2006 |
Quality of life improvement after hospital- based rehabilitation or home-based physical training in intermittent claudication.
Topics: Aged; Ambulatory Care; Clopidogrel; Combined Modality Therapy; Exercise Test; Female; Fibrinolytic A | 2006 |
[The assessment of TIKLO efficacy in patients with intermittent claudication].
Topics: Aged; Atherosclerosis; Exercise Test; Female; Humans; Intermittent Claudication; Lower Extremity; Ma | 2007 |
Rationale for the use of drugs inhibiting platelet function in claudicating patients with atherosclerotic leg arteries.
Topics: Anticoagulants; Arteriosclerosis; beta-Thromboglobulin; Blood Platelets; Clinical Trials as Topic; H | 1984 |
Registry of prospective clinical trials--fifth report.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Bypass; Coronary Disease; Dipyridamole; Double-Bl | 1982 |
Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.
Topics: Adult; Aged; Arteriosclerosis; Clinical Trials as Topic; Double-Blind Method; Humans; Intermittent C | 1982 |
Reduction of requirement for leg vascular surgery during long-term treatment of claudicant patients with ticlopidine: results from the Swedish Ticlopidine Multicentre Study (STIMS).
Topics: Female; Humans; Intermittent Claudication; Male; Proportional Hazards Models; Risk Factors; Ticlopid | 1995 |
Long-term effects of ticlopidine on lower limb blood flow, ankle/brachial index and symptoms in peripheral arteriosclerosis. A double-blind study. The STIMS Group in Lund. Swedish Ticlopidine Multicenter Study.
Topics: Adult; Aged; Arteriosclerosis; Double-Blind Method; Female; Follow-Up Studies; Humans; Intermittent | 1994 |
Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease.
Topics: Adult; Aged; Argentina; Double-Blind Method; Female; Follow-Up Studies; Humans; Intermittent Claudic | 1994 |
Blood viscosity during long-term treatment with ticlopidine in patients with intermittent claudication. A double-blind study.
Topics: Aged; Blood Viscosity; Double-Blind Method; Female; Follow-Up Studies; Hematocrit; Humans; Intermitt | 1993 |
Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Drug Therapy, Combination; Humans; Hypertension | 1996 |
The STIMS trial: the ticlopidine experience and its clinical applications. Swedish Ticlopidine Multicenter Study.
Topics: Cerebrovascular Disorders; Female; Humans; Intermittent Claudication; Male; Myocardial Infarction; P | 1996 |
[Role of antiaggregants in the treatment of arterial diseases of the lower limbs].
Topics: Humans; Intermittent Claudication; Ketanserin; Leg; Meta-Analysis as Topic; Peripheral Vascular Dise | 1991 |
Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study.
Topics: Aged; Cerebrovascular Disorders; Coronary Disease; Female; Humans; Intermittent Claudication; Ischem | 1990 |
Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial.
Topics: Blood Pressure; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Double-Blind Method; Female | 1989 |
Ticlopidine in the treatment of peripheral occlusive arterial disease.
Topics: Arterial Occlusive Diseases; Blood Flow Velocity; Clinical Trials as Topic; Exercise Test; Humans; I | 1989 |
Is it possible to reduce the risk of cardiovascular events in subjects suffering from intermittent claudication of the lower limbs?
Topics: Cardiovascular Diseases; Double-Blind Method; Female; Follow-Up Studies; Humans; Intermittent Claudi | 1989 |
Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications.
Topics: Clinical Trials as Topic; Double-Blind Method; Female; France; Humans; Intermittent Claudication; Ma | 1988 |
Long-term effects of ticlopidine on fibrinogen and haemorheology in patients with peripheral arterial disease.
Topics: Blood Viscosity; Fibrinogen; Follow-Up Studies; Humans; Intermittent Claudication; Ticlopidine; Time | 1988 |
14 other studies available for ticlopidine and Intermittent Claudication
| Article | Year |
|---|---|
Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; California; Cardiovascular Diseases; | 2015 |
Clinical significance of the clopidogrel-proton pump inhibitor interaction after peripheral endovascular intervention for claudication.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Chi-Square Distribution; Clopidogrel; Comorbidity; Co | 2012 |
Long-term results of plaque excision combined with aggressive pharmacotherapy in high-risk patients with advanced peripheral artery disease (SAVE a LEG registry).
Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Atherectomy; Atorvastatin; Cardiovasc | 2013 |
Physical training for intermittent claudication: a comparison of structured rehabilitation versus home-based training.
Topics: Aged; Aged, 80 and over; Clopidogrel; Exercise Therapy; Exercise Tolerance; Female; Follow-Up Studie | 2002 |
[Anticoagulation and antiaggregation in patients with peripheral arterial occlusive diseases].
Topics: Administration, Oral; Angioplasty, Balloon; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Bl | 2003 |
Effects of OP-1206 alpha-CD on walking dysfunction in the rat neuropathic intermittent claudication model: comparison with nifedipine, ticlopidine and cilostazol.
Topics: Alprostadil; Animals; Body Weight; Cilostazol; Disease Models, Animal; Exercise Test; Intermittent C | 2003 |
Role of antiplatelet therapy in cardiovascular disease III: Peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Clopidogrel; Female; Humans; Intermittent Claudication; M | 2004 |
Variability in responsiveness to clopidogrel in patients with intermittent claudication.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Drug Therapy, Combination; Female; Humans; Int | 2006 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |
Consensus document on intermittent claudication from the Central European Vascular Forum 1st edition - Abano Terme (Italy) - May 2005 2nd revision - Portroz (Slovenia) September 2007.
Topics: Aspirin; Carotid Stenosis; Clopidogrel; Disease Progression; Exercise Test; Humans; Intermittent Cla | 2008 |
Platelet survival, atherosclerotic intermittent claudication and ticlopidine.
Topics: Aged; Arteriosclerosis; Blood Platelets; Cell Survival; Humans; Indium; Intermittent Claudication; M | 1984 |
[The efficacy of ticlid in treating intermittent claudication in atherosclerotic stenosis of the arteries of the lower extremities].
Topics: Adult; Arteriosclerosis; Blood Coagulation Tests; Hemostasis; Humans; Intermittent Claudication; Leg | 1994 |
Effect of ticlopidine on the cutaneous circulation in peripheral vascular disease.
Topics: Aged; Blood Gas Monitoring, Transcutaneous; Drug Evaluation; Female; Gangrene; Humans; Intermittent | 1993 |
Multicriteria decision analysis for determining drug therapy for intermittent claudication.
Topics: Decision Support Techniques; Humans; Intermittent Claudication; Nafronyl; Pentoxifylline; Probabilit | 1998 |